MITOTANE

Details

Stereochemistry	RACEMIC
Molecular Formula	C14H10Cl4
Molecular Weight	320.041
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC(Cl)C(C1=CC=C(Cl)C=C1)C2=CC=CC=C2Cl

InChI

InChIKey=JWBOIMRXGHLCPP-UHFFFAOYSA-N

InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H

HIDE SMILES / InChI

Molecular Formula	C14H10Cl4
Molecular Weight	320.041
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.drugbank.ca/drugs/DB00648
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/cdi/mitotane.html

Mitotane is an oral chemotherapeutic agent indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types. Mitotane can best be described as an adrenal cytotoxic agent, although it can cause adrenal inhibition, apparently without cellular destruction. The administration of Mitotane alters the extra-adrenal metabolism of cortisol in man; leading to a reduction in measurable 17-hydroxy corticosteroids, even though plasma levels of corticosteroids do not fall. The drug apparently causes increased formation of 6-B-hydroxyl cortisol. Its biochemical mechanism of action is unknown, although data are available to suggest that the drug modifies the peripheral metabolism of steroids as well as directly suppressing the adrenal cortex. Mitotane is used for treatment of inoperable adrenocortical tumours; Cushing's syndrome

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cytochrome P450 11A1 4 Target ID: CHEMBL2033 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D00420	Inhibitor 8504
transformed cell apoptotic process 104 Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23507702	Activator 1447	38.0 µM [IC50]
cortisol biosynthetic process 1 Target ID: GO:0034651 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22546480	Inhibitor 8504
Cytochrome P450 11B1 9 Target ID: CHEMBL1908 Sources: http://www.drugbank.ca/drugs/DB00648	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Adrenal cortical carcinoma 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/016885s025lbl.pdf	Primary		Approved 8583	LYSODREN Approved Use LYSODREN is indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types. Launch Date 2003

C_max

Value	Dose	Co-administered	Analyte	Population
14.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24057287/	2 g 3 times / day multiple, oral dose: 2 g route of administration: Oral experiment type: MULTIPLE co-administered:		MITOTANE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
11.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24057287/	1 g 3 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered:		MITOTANE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Co-administered	Analyte	Population
790 mg × day/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24057287/	2 g 3 times / day multiple, oral dose: 2 g route of administration: Oral experiment type: MULTIPLE co-administered:		MITOTANE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: FED
543 mg × day/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24057287/	1 g 3 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered:		MITOTANE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Co-administered	Analyte	Population
105 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/38244214/	0.93 g 3 times / day multiple, oral dose: 0.93 g route of administration: Oral experiment type: MULTIPLE co-administered:		MITOTANE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 g 3 times / day multiple, oral Recommended Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22048971	unhealthy, 51.4+/-11.9 Health Status: unhealthy Age Group: 51.4+/-11.9 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/22048971	Disc. AE: Anorexia, Nausea... AEs leading to discontinuation/dose reduction: Anorexia (grade 1-2) Nausea (grade 1-2) Vomiting (grade 1-2) Diarrhea (grade 1-2) Abdominal pain (grade 1-2) Sources: https://pubmed.ncbi.nlm.nih.gov/22048971
2 g 3 times / day multiple, oral Recommended Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf	Disc. AE: Central nervous system toxicity, Fetal damage... AEs leading to discontinuation/dose reduction: Central nervous system toxicity Fetal damage Ovarian cyst Adrenal insufficiency Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf

AEs

AE	Significance	Dose	Population
Abdominal pain	grade 1-2 Disc. AE	2 g 3 times / day multiple, oral Recommended Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22048971	unhealthy, 51.4+/-11.9 Health Status: unhealthy Age Group: 51.4+/-11.9 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/22048971
Anorexia	grade 1-2 Disc. AE	2 g 3 times / day multiple, oral Recommended Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22048971	unhealthy, 51.4+/-11.9 Health Status: unhealthy Age Group: 51.4+/-11.9 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/22048971
Diarrhea	grade 1-2 Disc. AE	2 g 3 times / day multiple, oral Recommended Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22048971	unhealthy, 51.4+/-11.9 Health Status: unhealthy Age Group: 51.4+/-11.9 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/22048971
Nausea	grade 1-2 Disc. AE	2 g 3 times / day multiple, oral Recommended Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22048971	unhealthy, 51.4+/-11.9 Health Status: unhealthy Age Group: 51.4+/-11.9 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/22048971
Vomiting	grade 1-2 Disc. AE	2 g 3 times / day multiple, oral Recommended Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/22048971	unhealthy, 51.4+/-11.9 Health Status: unhealthy Age Group: 51.4+/-11.9 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/22048971
Adrenal insufficiency	Disc. AE	2 g 3 times / day multiple, oral Recommended Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf
Central nervous system toxicity	Disc. AE	2 g 3 times / day multiple, oral Recommended Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf
Fetal damage	Disc. AE	2 g 3 times / day multiple, oral Recommended Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf
Ovarian cyst	Disc. AE	2 g 3 times / day multiple, oral Recommended Dose: 2 g, 3 times / day Route: oral Route: multiple Dose: 2 g, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 2633	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf#page=4 Page: 4.0	strong		likely (co-administration study) Comment: LYSODREN’s CYP induction effect leads to an increase in dosage requirements for warfarin. Closely monitor patients for a change in anticoagulant dosage requirements when administering LYSODREN to patients receiving coumarin-type anticoagulants Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016885s027lbl.pdf#page=4 Page: 4.0

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY558683	https://www.001chemical.com/chem/53-19-0
3B Scientific (Wuhan) Corp	3B3-026423	http://www.3bsc.com/index/pro_info.php?id=47662
AA Blocks	AA00ILLB	http://www.aablocks.com/goods/Goods/detail?id=AA00ILLB
Aaron Chemicals	AR00IMD3	http://www.aaronchem.com/53-19-0
abcr GmbH	AB509180	http://www.abcr.com/shop/en/AB509180
AbMole Bioscience	M3425	http://www.abmole.com/products/mitotane.html
Achemtek	0104-044397	http://www.achemtek.com/53-19-0
AHH Chemical co.,ltd	MT-19139	http://www.ahhchemical.com/product/MT-19139.html
AK Scientific, Inc. (AKSCI)	67599	http://www.aksci.com/item_detail.php?cat=67599
Alfa Chemistry	AP53190-A	https://reagents.alfa-chemistry.com/product/2-4-ddd-cas-53-19-0-12645.html
Alfa Chemistry	AP53190-B	https://reagents.alfa-chemistry.com/product/mitotane-cas-53-19-0-12646.html
Alsachim	1837	http://www.alsachim.com/product-C2719-glo.bal-view.html
Ambeed	A817688	https://www.ambeed.com/products/53-19-0.html
Angene	AGN-PC-088NK5	http://www.angenechemical.com/productshow/AGN-PC-088NK5.html
Ark Pharm	AK546750	http://www.arkpharminc.com/products/53-19-0.html
Aurora Fine Chemicals LLC	K02.120.487	http://online.aurorafinechemicals.com/info?ID=K02.120.487
Aurum Pharmatech LLC	W-5031	http://www.Aurumpharmatech.com/Product/ProductDetails/W_5031
Axon MedChem	3248	https://www.axonmedchem.com/product/3248
BioChemPartner	BCP11663	http://www.biochempartner.com/53-19-0-BCP11663
BioCrick	BCC3815	http://www.biocrick.com/Mitotane-Lsodren-BCC3815.html
BLD Pharm	BD145903	http://www.bldpharm.com/products/53-19-0.html
Capot Chemical	14974	http://www.capotchem.com/en/14974.htm
Capot Chemical	PubChem14974	http://www.capotchem.com/en/14974.htm
Chem Scene	CS-1500	http://www.chemscene.com/53-19-0.html
Chemenu	CM110274	http://www.chemenu.com/products/CM110274
ChemMol	49425872	http://www.chemmol.com/chemmol/49425872.html
Chemspace	CSSB00000519455	https://chem-space.com/CSSB00000519455
Clearsynth	CS-T-58863	https://www.clearsynth.com/en/CST58863.html
CSNpharm	CSN11593	https://www.csnpharm.com/products/mitotane.html
DC Chemicals	DCAPI1234	http://www.dcchemicals.com//product_show-Mitotane_Lysodren_.html
Enamine	Z425389592	https://www.enaminestore.com/catalog/Z425389592
eNovation Chemicals	D672644	https://www.enovationchem.com/ProductDetails.asp?ProductID=D672644
Finetech	FT-0605518	http://www.finetechnology-ind.com/prod/detail/pub/53-19-0.html
Glentham Life Sciences	GL0573	http://www.glentham.com/products/product/GL0573/
Hairui	HR124477	http://www.hairuichem.com/en/product/53-19-0.html
iChemical	EBD36309	http://www.ichemical.com/products/53-19-0.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
Lab Network	LN01289322	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01289322
LGC Standards	DRE-C12030000	https://www.lgcstandards.com/US/en/p/DRE-C12030000
LGC Standards	DRE-L12030000CY	https://www.lgcstandards.com/US/en/p/DRE-L12030000CY
LGC Standards	DRE-XA12030000CY	https://www.lgcstandards.com/US/en/p/DRE-XA12030000CY
mcule	MCULE-2068358149	https://mcule.com/MCULE-2068358149/
MedChem Express	HY-13690	https://www.medchemexpress.com/mitotane.html
Molcore	MC558683	https://www.molcore.com/product/53-19-0
OChem	4284	http://www.ocheminc.com/index.php?act=psearch&pid=000M850
Sigma-Aldrich	1445007_USP	http://www.sigmaaldrich.com/catalog/product/usp/1445007?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	25925_SIGMA	http://www.sigmaaldrich.com/catalog/product/sigma/25925?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	35485_SIAL	http://www.sigmaaldrich.com/catalog/product/sial/35485?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	49015_SUPELCO	http://www.sigmaaldrich.com/catalog/product/supelco/49015?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	N12706_SUPELCO	http://www.sigmaaldrich.com/catalog/product/supelco/n12706?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech	S013106	http://www.sinfoobiotech.com/product/1016504
Smolecule	S535549	http://www.smolecule.com/products/s535549
THE BioTek	bt-276001	https://www.thebiotek.com/product/inhibitors/bt-276001
Yuhao Chemical	LQ0013	http://www.chemyuhao.com/53-19-0.html

PubMed

Title	Date	PubMed
Human sex hormone-binding globulin binding affinities of 125 structurally diverse chemicals and comparison with their binding to androgen receptor, estrogen receptor, and α-fetoprotein.	2015-02	25349334
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.	2013-09-05	23769903
Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.	2013-07	23585556
Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells.	2013-06	23696597
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane.	2013-06	23524664
Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.	2013-06	23507702
The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells.	2013-03	23254310
Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor.	2013-03	23179081
[Surgery of the adrenal gland].	2012-11	23330457
Differential effect of DDT, DDE, and DDD on COX-2 expression in the human trophoblast derived HTR-8/SVneo cells.	2012-11	23132776
Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study.	2012-09	22966885
The organochlorine o,p'-DDT plays a role in coactivator-mediated MAPK crosstalk in MCF-7 breast cancer cells.	2012-09	22609851
Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells.	2012-08-16	22546480
Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer.	2012-06-15	22547773
Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer.	2012-01	22156929
Biphasic hormonal responses to the adrenocorticolytic DDT metabolite 3-methylsulfonyl-DDE in human cells.	2010-02-01	19900470
(2S)-1,1-Dichloro-2-(2-chloro-phen-yl)-2-(4-chloro-phen-yl)ethane.	2009-01-14	21581907
Cushing's disease in dogs and humans.	2009-01	19153526
Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.	2009-01	18854392
Organochlorine-mediated potentiation of the general coactivator p300 through p38 mitogen-activated protein kinase.	2009-01	18791200
Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.	2008-06	18509009
A novel pretreatment approach for fast determination of organochlorine pesticides in biotic samples.	2008-05	18437618
Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.	2008-03	18310271
Effect of o,p'-DDD and Li+ on apoptotic DNA fragmentation in conventionally normal and tumour tissues of human adrenal cortex.	2007-11-23	18030749
Tailored hormonal therapy in secretory adrenocortical cancer.	2007-07	17675396
Adrenocortical cancer: pathophysiology and clinical management.	2007-03	17395972
Acute hepatopathy associated with mitotane administration in a dog.	2006-07-11	16822769
Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans.	2006-06	16551731
Recombinant human estrogen, androgen and progesterone receptors for detection of potential endocrine disruptors.	2004-02	14579009
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor.	2003-10	14565775
Development of a fish reporter gene system for the assessment of estrogenic compounds and sewage treatment plant effluents.	2002-09	12206426
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.	2002-05-01	12015757
Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p'-DDD in human adrenal zona fasciculata/reticularis.	2002-03	11889204
Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells.	1998-07	9705896
A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile.	1997-03	9815696
Interaction of environmental chemicals with the estrogen and progesterone receptors from the oviduct of the American alligator.	1996-12	9118873
Identification of environmental chemicals with estrogenic activity using a combination of in vitro assays.	1996-10	8930550
Alterations in Ca2+ transport ATPase and P-glycoprotein expression can mediate resistance to thapsigargin.	1994-03-18	7907587
Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma.	1993	8453685
Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer.	1993	8098948
Neuropsychologic and neurologic side effects of mitotane and reversibility of symptoms.	1992-09	1517795
Possible mechanism and treatment of o,p'DDD-induced hypercholesterolaemia.	1992-09	1480741
Reversible mental deterioration and neurological disturbances with o,p'-DDD therapy.	1992	1320517
Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas.	1991-07	1675220
[Idiopathic intracranial hypertension during treatment of Cushing's disease with mitotane].	1987-12-12	2963295
[Neurotoxicity of mitotane therapy of adrenocortical carcinoma (5 cases) and Cushing's syndrome (7 cases)].	1987-05-23	2954144
Toxicity, ultrastructural effects, and metabolic studies with 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane(o,p'-DDD) and its methyl analog in the guinea pig and rat.	1987-01	3798445
Primary hypogonadism associated with o,p' DDD (mitotane) therapy.	1987	3441014
[The effects of o,p'-DDD on human adrenal steroid synthesis].	1984-07-20	6094274
Mitotane use in inoperable adrenal cortical carcinoma.	1973-03-05	4739370

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Adrenal Cortical Carcinoma -Initial Dose: 2 to 6 g orally per day in 3 to 4 divided doses -Maintenance Dose: 9 to 10 g orally per day in 3 to 4 divided doses -Maximum Dose: May increase up to 16 g orally per day, if tolerated, in 3 to 4 divided doses; the highest doses used in studies were 18 to 19 g per day.

Route of Administration: Oral

In Vitro Use Guide

Mitotane (10-40uM) inhibited basal and cAMP-induced cortisol secretion in human adrenocortical cancer NCI-H295 cells.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 21:25:47 GMT 2025` Edited by `admin` on `Mon Mar 31 21:25:47 GMT 2025`
Record UNII	78E4J5IB5J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHLODITAN

Preferred Name

English

MITOTANE

Official Name

English

Mitotane [WHO-DD]

Common Name

English

MITOTANE [EMA EPAR]

Common Name

English

MITOTANE [USAN]

Common Name

English

O,P'-DDD

Common Name

English

MITOTANE [MI]

Common Name

English

MITOTANE [USP IMPURITY]

Common Name

English

MITOTANE [ORANGE BOOK]

Common Name

English

CB-313

Code

English

O,P'-TDE

Common Name

English

NSC-38721

Code

English

mitotane [INN]

Common Name

English

CB 313

Code

English

MITOTANE [MART.]

Common Name

English

O,P'-DDD,O P'-TDE

Common Name

English

MITOTANE [HSDB]

Common Name

English

MITOTAN

Common Name

English

CHLODITHANE

Brand Name

English

OPEPRIM

Brand Name

English

MITOTANE [JAN]

Common Name

English

MITOTANE [USP-RS]

Common Name

English

BENZENE, 1-CHLORO-2-(2,2-DICHLORO-1-(4-CHLOROPHENYL)ETHYL)-, (±)-

Systematic Name

English

(±)-1,1-DICHLORO-2-(O-CHLOROPHENYL)-2-(P-CHLOROPHENYL)ETHANE

Common Name

English

LYSODREN

Brand Name

English

MITOTANE [USP MONOGRAPH]

Common Name

English

BENZENE, 1-CHLORO-2-(2,2-DICHLORO-1-(4-CHLOROPHENYL)ETHYL)-

Systematic Name

English

MITOTANE [VANDF]

Common Name

English

Classification Tree Code System Code

WHO-ATC

L01XX23